Ramesh Ganesan
Vascular Biology Center, Georgia Health Sciences University, Augusta, GA 30912, USA.
Recent Pat Biomark. 2012 Sep;2(3):202-208. doi: 10.2174/2210309011202030202.
Acute kidney injury (AKI) is a common problem in the hospital setting and intensive care unit. Despite improved understanding, there are no effective therapies available to treat AKI. AKI is often diagnosed late and, therefore, identification of a biomarker that will facilitate early diagnosis of AKI and provide a prognosis is desirable. The recent identification of a novel biomarker, netrin-1, that is capable of diagnosing early during the course of kidney injury has created much interest in this molecule. In this paper, we review recent progress made in understanding netrin-1 as a biomarker and therapeutic molecule for acute and chronic kidney diseases. We also discuss both the usefulness of netrin-1 as a biomarker of other diseases and as a possible therapeutic agent and relevant patents for inflammatory diseases.
急性肾损伤(AKI)是医院环境和重症监护病房中常见的问题。尽管对其认识有所提高,但目前尚无有效的治疗方法来治疗AKI。AKI常常诊断较晚,因此,找到一种有助于AKI早期诊断并提供预后信息的生物标志物是很有必要的。最近发现了一种新型生物标志物——netrin-1,它能够在肾损伤过程中早期进行诊断,这引起了人们对该分子的极大兴趣。在本文中,我们综述了在将netrin-1理解为急性和慢性肾脏疾病的生物标志物及治疗分子方面所取得的最新进展。我们还讨论了netrin-1作为其他疾病生物标志物的用途、作为可能的治疗剂的用途以及炎症性疾病的相关专利。